Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies
The DOI matches its Crossref record; 423 of the 423 references it cites were found in a registry or an index.
Abstract
Continuously increasing understanding of the molecular triggers responsible for the onset of diseases, paralleled by an equally dynamic evolution of chemical synthesis and screening methods, offers an abundance of pharmacological agents with a potential to become new successful drugs. However, before patients can benefit of newly developed pharmaceuticals, stringent safety filters need to be applied to weed out unfavourable drug candidates. Cost effectiveness and the need to identify compound liabilities, without exposing humans to unnecessary risks, has stimulated the shift of the safety studies to the earliest stages of drug discovery and development. In this regard, in vivo relevant organotypic in vitro models have high potential to revolutionize the preclinical safety testing. They can enable automation of the process, to match the requirements of high-throughput screening approaches, while satisfying ethical considerations. Cultures of primary hepatocytes became already an inherent part of the preclinical pharmaco-toxicological testing battery, yet their routine use, particularly for long-term assays, is limited by the progressive deterioration of liver-specific features. The availability of suitable hepatic and other organ-specific in vitro models is, however, of paramount importance in the light of changing European legal regulations in the field of chemical compounds of different origin, which gradually restrict the use of animal studies for safety assessment, as curr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased albumin secretion from spheroids compared to cell monolayers, as seen here, is consistent with observations reported in literature, which indicates that culturing the cells as spheroids may enhance homotypic cell-cell interactions within aggregated hepatocytes and improve functional outcomes of the hepatic construct [25,48].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [48]
In the citing paper
“Increased albumin secretion from spheroids compared to cell monolayers, as seen here, is consistent with observations reported in literature, which indicates that culturing the cells as spheroids may enhance homotypic cell-cell interactions within aggregated hepatocytes and improve functional outcomes of the hepatic construct [25,48].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [48]
In the citing paper
“Although scarcely distributed, the ECM is an integral part of the complex liver architecture and the restoration of cell-ECM contacts is crucial for the preservation of the differentiated hepatic phenotype in cell culture (Fraczek et al., 2013[12]; Ye et al., 2019[48]).”
From Optimization of extracellular matrix for primary human hepatocyte cultures using mixed collagen-matrigel matrices (2023) · cites this paper as Fraczek et al., 2013[12]
In the citing paper
“The application of primary human hepatocytes following isolation from human tissue is well accepted to be compromised by the process of dedifferentiation.”
From Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile (2017) · cites this paper as Fraczek et al. 2013
In the citing paper
“HNF1α, C/EBP and HNF1β were amongst the most significantly associated regulators with the loss of metabolic competence.”
From Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile (2017) · cites this paper as Fraczek et al. 2013
Citations
Cites
1 retracted
Items 401–423 of 423
Fraczek, J., Vinken, M., Tourwé, D., Vanhaecke, T., & Rogiers, V. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9659-8 · Cited by 15
Self-citationThe Behaviors of Long‐Term Cryopreserved Human Hepatocytes on Different Biomaterials
Lu, J., Wang, C., & Young, T. (2011) · Artificial Organs · doi:10.1111/j.1525-1594.2010.01191.x · Cited by 14 · cited 1×
“There is a fast growing list of other biomaterials, including peptides and polymers in the form of nanofibers or hydrogels, which were proposed as novel synthetic support matrices for hepatocyte cultivation (Ananthanarayanan et al. 2011; Wu et al. 2010; Gotoh et al. 2011; Lu et al. 2011; Williams et al. 2011; Schutte…”
BackgroundRodrigues, E., Vilarem, M., Ribeiro, V., Maurel, P., & Lechner, M. C. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03413.x · Cited by 14
Characterization of the Murine Coagulation Factor X Promoter
Wilberding, J., & Castellino, F. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614167 · Cited by 14
Yoo, E. J., & Lee, B. M. (2005) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390500182511 · Cited by 13
CCAAT/enhancer-binding protein-alpha-dependent transactivation of CYP2C12 in rat hepatocytes
Tollet, P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.12.1771 · Cited by 13
Donato, M. T., Gómez-Lechón, M. J., & Castell, J. V. (1991) · Toxicology in Vitro · doi:10.1016/0887-2333(91)90067-n · Cited by 12
Hsiang, C., Marten, N. W., & Straus, D. S. (1999) · Biochemical Journal · doi:10.1042/bj3380241 · Cited by 12
Discovering Networks of Perturbed Biological Processes in Hepatocyte Cultures
Lasher, C. D., Rajagopalan, P., & Murali, T. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015247 · Cited by 12
Wang, J., Zong, C., Shi, D., Wang, W., Shen, D., Liu, L., Tong, X., Zheng, Q., & Gao, C. (2011) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.393 · Cited by 12
Cell cultures as in vitro tools for biotransformation studies
Elaut, G., Rogiers, V., Papeleu, P., Vanhaecke, T., & Pandalai, S. G. (2002) · VUBIR (Vrije Universiteit Brussel) · Cited by 12
Self-citationHepatocytes: Methods and Protocols
(2010) · Methods in molecular biology · doi:10.1007/978-1-60761-688-7 · Cited by 12
Fraczek, J., Deleu, S., Lukaszuk, A., Doktorova, T. Y., Tourwé, D., Geerts, A. E., Vanhaecke, T., Vanderkerken, K., & Rogiers, V. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9180-x · Cited by 11
Self-citationHistone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Papeleu, P., Vanhaecke, T., & Rogiers, V. (2006) · Current Enzyme Inhibition · doi:10.2174/157340806775473517 · Cited by 11
Self-citationRegulation of CYP1A2 by histone deacetylase inhibitors in mouse hepatocytes
Jin, B., & Ryu, D. (2004) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20017 · Cited by 11
Inhibition of Hepatocyte Growth Factor Production in Human Fibroblasts by Ursodeoxycholic Acid
Hiramatsu, K., Matsumoto, Y., Miyazaki, M., Tsubouchi, H., Yamamoto, I., & Gohda, E. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.619 · Cited by 9
Nishimura, M., Ejiri, Y., Kishimoto, S., Suzuki, S. O., Satoh, T., Horie, T., Narimatsu, S., & Naito, S. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rg-069 · Cited by 9
Papeleu, P., Loyer, P., Vanhaecke, T., Henkens, T., Elaut, G., Guguen‐Guillouzo, C., & Rogiers, V. (2004) · Alternatives to Laboratory Animals · doi:10.1177/026119290403201s10 · Cited by 9
Self-citationCorlu, A., Lamy, I., Ilyin, G. P., Fardel, O., Kneip, B., Jossic-Corcos, C. L., & Guguen‐Guillouzo, C. (1998) · PubMed · Cited by 9
Application of Short‐ and Long‐Term Hepatocyte Cultures to Predict Toxicities
Tuschl, G., Hrach, J., Hewitt, P. G., & Mueller, S. O. (2007) · Wiley eBooks · doi:10.1002/9780470516751.ch7 · Cited by 8
Henkens, T., Vinken, M., Lukaszuk, A., Tourwé, D. A., Vanhaecke, T., & Rogiers, V. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.02.002 · Cited by 8
Self-citationMiyazaki, M., MARS, W., MICHALOPOULOS, G. K., & Namba, M. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.1998.13.s1.78 · Cited by 6
Use of Hepatocytes for Characterizing a Candidate Drug's Metabolism and Drug Interaction Potential
Nallani, S. C., Strong, J. M., & Huang, S. M. (2007) · Wiley eBooks · doi:10.1002/9780470516751.ch3 · Cited by 1
Research works printed but not linked: 1
- Nishimura M, Ejiri Y, Kishimoto S, Suzuki S, Satoh T, Horie T, Narimatsu S, Naito S (2011) Expression levels of drug-metabolizing enzyme, transporter, and nuclear receptor mRNAs in a novel three-dimensional culture system for human hepatocytes using micro-space plates. Drug Metab Pharmacokinet 26(2):137–144 · DOI
Cited by
McGill, M. R., & Jaeschke, H. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1007-6 · Cited by 704
“Phenobarbital), can be added to the culture medium (171,174,175).”
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Maturation of Induced Pluripotent Stem Cell Derived Hepatocytes by 3D-Culture
Gieseck III, R. L., Hannan, N. R. F., Bort, R., Hanley, N. A., Drake, R. A. L., Cameron, G. W. W., Wynn, T. A., & Vallier, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086372 · Cited by 197
“This is suggestive of contact-dependent apoptosis similar to that seen in low density PHH dedifferentiation [1,2].”
Engineering a perfusable 3D human liver platform from iPS cells
Schepers, A., Li, C., Chhabra, A., Seney, B. T., & Bhatia, S. (2016) · Lab on a Chip · doi:10.1039/c6lc00598e · Cited by 176
Heslop, J. A., Rowe, C., Walsh, J., Sison-Young, R., Jenkins, R., Kamalian, L., Kia, R., Hay, D., Jones, R. P., Malik, H. Z., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1694-y · Cited by 141
“Furthermore, following isolation, primary human hepatocytes undergo a rapid dedifferentiation process in which many unique hepatocyte characteristics are lost, reducing the physiological relevance of the model (Fraczek et al. 2013; Godoy et al. 2013).”
BackgroundInfluential
Metadata
- Authors
- Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M.
- Affiliations
- Vrije Universiteit Brussel (BE)
- Corresponding author
- Fraczek, J.
- Venue
- Archives of Toxicology
- Published
- 2012-12-15
- Volume
- 87
- Issue
- 4
- Pages
- 577-610
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2018187848
- Cited by
- 119
- References
- 422
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 9 · 2022: 10 · 2021: 11 · 2020: 6 · 2019: 13 · 2018: 10 · 2017: 7 · 2016: 12 · 2015: 9 · 2014: 14 · 2013: 5
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archives of Toxicology (publishedVersion)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- primary hepatocyte culture, hepatocyte dedifferentiation, preclinical safety, drug toxicity, high-throughput screening, alternatives to animal testing, long-term hepatocyte culture
- MeSH terms
- Animals, Animal Testing Alternatives, Cells, Cultured, Drug Evaluation, Preclinical, Humans, Xenobiotics, Apoptosis, Hepatocytes, Mice, Rats, Cell Dedifferentiation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.